Stem Cell and Exosome Therapy in the UAE: What's Actually Happening

What This Article Covers

The UAE, and Dubai in particular, has spent the better part of a decade trying to become a serious regenerative-medicine hub rather than just a destination for unregulated "stem cell tourism." That effort reached a real milestone on February 28, 2026, when a new Dubai Health Authority (DHA) standard for stem cell services took effect — the clearest, most restrictive rulebook the emirate has issued yet. This article looks at what the new standard actually requires, what it leaves unresolved (especially for exosome products), and how Dubai's approach compares with regulatory gray zones elsewhere.

A Decade of Incremental Regulation

Dubai's regulatory involvement with stem cells isn't new. Back in September 2018, the DHA launched a formal pathway for autologous stem cell therapy (using a patient's own cells) and established a Stem Cell Scientific Board to issue guidance, describing its approach at the time as deliberately "incremental" — starting with facility and practitioner licensing before building out fuller clinical guidelines. Dr. Marwan Al Mulla, the DHA's CEO of health regulation, framed the goal as keeping Dubai "at the forefront of cutting-edge innovation" while still ensuring "high-quality and safe" treatment. That 2018 framework was a starting point, not a finished system, and the gap between "licensed to offer autologous stem cell therapy" and "proven to work for a given condition" remained wide for years afterward.

The New 2026 Standard

The document that closes much of that gap — "Standards for Stem Cell Services," issued December 31, 2025, and effective February 28, 2026 — is considerably more prescriptive. It requires any facility offering stem cell services to declare its full scope of activity and obtain separate DHA approval for each one, whether that's banking, processing and manufacturing (which additionally needs Emirates Drug Establishment approval), or direct clinical use. Clinical or research use requires sign-off from both an Institutional Review Board and the DHA's own Ethics Committee, and any outsourced processing must be governed by a written agreement with an accredited lab.

The most consequential line in the standard is this: "Licensed stem cell practices shall be restricted to the clinical use of autologous cells and products that are minimally manipulated, unless specifically authorized under a DHA-approved clinical trial." In plain terms, routine clinics may still offer a patient's own, lightly processed cells — but allogeneic (donor-derived) stem cell products for non-transplant purposes are barred outside a formal, DHA-approved trial. The standard goes further on marketing than most comparable frameworks globally, stating flatly that "commercial, aesthetic, or wellness-based use of stem cells is strictly prohibited outside these approved pathways," and that "misleading or exaggerated claims regarding stem cell benefits are prohibited" in any donor or patient-facing materials.

The Exosome Gap

Here is where the new rules are honest about their own limits rather than papering over them. The standard does define exosomes — as "extracellular vesicles secreted by stem cells that mediate intercellular communication" — acknowledging they exist as a distinct product category clinics are already using. But it stops there: no licensing category, approval pathway, or manufacturing standard is specified for exosome products the way there is for stem cells themselves. That leaves exosome-based offerings (increasingly marketed in the region for skin, hair, and joint applications) in the same kind of regulatory limbo that has drawn FDA scrutiny in the United States, where exosome products remain unapproved as drugs.

That American comparison isn't hypothetical. The FDA has warned since 2019 that "exosome products have not been approved for any use," after a 2019 case in which patients treated with an unapproved umbilical cord blood-derived exosome product experienced serious adverse events including bacterial infections. As recently as May 2025, the FDA issued a warning letter to a U.S. clinic (Supreme Rejuvenation, LLC) over marketed stem cell and exosome offerings. Dubai's new standard doesn't reach that level of explicit warning, but by naming exosomes without regulating them, it effectively flags the same open question American regulators have been wrestling with for years: what happens to a biologic product that clinics are already selling faster than science, or regulators, can catch up to it.

Why This Matters for Patients Considering Treatment in the UAE

None of this means every clinic in Dubai is operating improperly — many now operate within the licensed, autologous, minimally-manipulated framework the DHA has built. But the new standard is itself an admission that enforcement has been a real problem worth tightening: you don't write a rule banning "misleading or exaggerated claims" about a treatment category unless such claims have been circulating. For a prospective patient, the practical takeaway is straightforward: a clinic's ability to legally offer autologous stem cell services under DHA licensing says nothing about whether that specific treatment is proven effective for a specific condition, and it says even less for exosome products, which currently sit outside any dedicated approval pathway anywhere in the world, UAE included.

Bottom Line

Dubai's February 2026 stem cell standard is a genuine regulatory tightening — real licensing requirements, a hard restriction to autologous, minimally manipulated cells for routine use, and an explicit ban on wellness and aesthetic marketing outside approved pathways. That's a meaningfully more rigorous framework than the loosely enforced "incremental" approach the DHA started with in 2018, and it deserves recognition as such. What it does not do is resolve the exosome question, or make any specific stem cell treatment offered there evidence-based. Patients evaluating regenerative medicine options in the UAE, as anywhere else, should ask what a clinic is actually licensed for, whether a specific product has any DHA or Emirates Drug Establishment approval, and whether the evidence for their specific condition comes from a registered clinical trial rather than marketing material.